Disease spotlight: LHON

Newsletters and Deep Dive digital magazine
Co-chaired by Lord James O’Shaughnessy and Professor Mike Bewick, former deputy national medical director of NHS England (present online), the
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
How can digital and AI optimise the delivery of patient support programs in cancer?
Each year, pharma and life sciences invest large amounts of time and money in creating content designed to attract HCPs and call them to action.
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector. But, al
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessme
Industry-dedicated summit focused on advancing the best-in-class kinase inhibitor products
The 5th Annual Cell Engager Summit is back in Boston, MA this year
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox